GlaxoSmithKline said it would buy cancer-focused drug company Tesaro for about $4.16 billion, positioning the health-care giant in a promising, but fiercely competitive, area of medicine.

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

GlaxoSmithKline downgraded full-year earnings expectations, as its second-quarter profit was hit by currency moves, weak sales of its respiratory drugs and the continuing bribery investigation in ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Photo by Flickr user Ian Wilson Doctors will no longer be paid to speak on behalf of GlaxoSmithKline and its products, the British drug maker said Tuesday. In addition, the pharmaceutical company ...

Pharmaceutical comipany GlaxoSmithKline is under scrutiny following the death of children in Argentina. Parents believe that the experimental vaccines may be the cause of infant deaths.

GlaxoSmithKline's chief executive officer said in an email to the company’s employees that Slaoui’s name would be removed from its research and development facility in Rockville, Md.

Last week, the U.S. Department of Justice announced that GlaxoSmithKline had agreed to pay $3 billion in criminal and civil fines for its misdeeds in inappropriately marketing Paxil and another ...

GlaxoSmithKline Plc is partnering with the Ivy Brain Tumor Center to test one of its key oncology medicines against brain cancer as the British pharmaceutical giant looks to expand the drug’s use.

GlaxoSmithKline’s (GSK) materially understated profits and alarming and material disclosures in the 10-Ks of Squarespace (SQSP), VBI Vaccines (VBIV), and Research Frontiers (REFR).

Sanofi and GlaxoSmithKline have launched a new study of their coronavirus vaccine after a previous trial produced disappointing results. The drugmakers pushed back the rollout of their ...

GlaxoSmithKline Plc (GSK.L) has hired two banks to help advise it on listing its consumer unit next year and on defense against a potential activist campaign from Elliott Investment Management ...